General Information of DTT (ID: TTJW4LU)

DTT Name Phosphodiesterase 10A (PDE10) DTT Info
Gene Name PDE10A

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
9 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lu AF11167 DMJOYNZ Schizophrenia 6A20 Phase 2 [1]
OMS824 DMA4OGL Huntington disease 8A01.10 Phase 2 [2]
PF-02545920 DMJPE61 Huntington disease 8A01.10 Phase 2 [3]
TAK-063 DMP1873 Schizophrenia 6A20 Phase 2 [4]
Tofisopam DMTGNWU Hyperuricaemia 5C55.Y Phase 2 [5]
FRM-6308 DMNCOE1 Schizophrenia 6A20 Phase 1b [6]
AMG 579 DMRMC7U Schizophrenia 6A20 Phase 1 [7]
PBF-999 DMBSQH9 Huntington disease 8A01.10 Phase 1 [8]
RG7203 DMYX4NP Schizophrenia 6A20 Phase 1 [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Clinical Trial Drug(s)
31 Patented Agent(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
1,2,4-triazole [4,3-a]quinoxaline derivative 1 DMD9QW2 N. A. N. A. Patented [10]
1,2,4-triazole [4,3-a]quinoxaline derivative 2 DM3DIW9 N. A. N. A. Patented [10]
1,2,4-triazole [4,3-a]quinoxaline derivative 3 DMKXRYM N. A. N. A. Patented [10]
1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 3 DM62K40 N. A. N. A. Patented [10]
1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 4 DMQSTG9 N. A. N. A. Patented [10]
1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 5 DM9E0ZD N. A. N. A. Patented [10]
1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 6 DM826JW N. A. N. A. Patented [10]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 1 DMQBH81 N. A. N. A. Patented [10]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2 DMS3ROL N. A. N. A. Patented [10]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 3 DMZ61T8 N. A. N. A. Patented [10]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 4 DMKR5ZO N. A. N. A. Patented [10]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 5 DM7UAKH N. A. N. A. Patented [10]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 6 DMKRUAN N. A. N. A. Patented [10]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 7 DMINBJM N. A. N. A. Patented [10]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 8 DM42EST N. A. N. A. Patented [10]
Imidazo[5,1-c][1,2,4]benzotriazine derivative 1 DMUB4QL N. A. N. A. Patented [10]
Imidazo[5,1-c][1,2,4]benzotriazine derivative 2 DMB8AJP N. A. N. A. Patented [10]
Imidazo[5,1-c][1,2,4]benzotriazine derivative 3 DMYX684 N. A. N. A. Patented [10]
Imidazo[5,1-c][1,2,4]benzotriazine derivative 4 DMWF4S7 N. A. N. A. Patented [10]
PMID27321640-Compound-58 DM0NYK3 N. A. N. A. Patented [10]
PMID27321640-Compound-59 DM41B5O N. A. N. A. Patented [10]
Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 1 DMHKRVL N. A. N. A. Patented [10]
Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 2 DMUO25Y N. A. N. A. Patented [10]
Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 3 DMAEYNT N. A. N. A. Patented [10]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1 DMC8935 N. A. N. A. Patented [10]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2 DM4CSBD N. A. N. A. Patented [10]
Triazolo-pyridine derivative 2 DMXPQ24 N. A. N. A. Patented [10]
Triazolo-pyridine derivative 3 DMQL1TV N. A. N. A. Patented [10]
Triazolo-pyridine derivative 4 DM5ZQKS N. A. N. A. Patented [10]
Triazolo-pyridine derivative 5 DM1R205 N. A. N. A. Patented [10]
Triazolo-pyridine derivative 6 DMX4WFP N. A. N. A. Patented [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 31 Patented Agent(s)
Molecule Interaction Atlas

References

1 PDE10A Inhibitors-Clinical Failure or Window Into Antipsychotic Drug Action?. Front Neurosci. 2021 Jan 20;14:600178.
2 New Drugs/Drug News. P T. 2013 November; 38(11): 667-672.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Characterization of Binding and Inhibitory Properties of TAK-063, a Novel Phosphodiesterase 10A Inhibitor. PLoS One. 2015; 10(3): e0122197.
5 The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
6 Massive schizophrenia genomics study offers new drug directions. Nat Rev Drug Discov. 2014 Sep;13(9):641-2.
7 Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase10A (PDE10A). J Med Chem. 2014 Aug 14;57(15):6632-41.
8 Clinical pipeline report, company report or official report of Palobiofarma.
9 Synaptic synopsis. SciBX 6(41); doi:10.1038/scibx.2013.1153. Oct. 24, 2013
10 Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.